Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Comments

No comments yet. Be the first!